As the lead government agency responsible for the development of industrial infrastructure to support and catalyse the growth of industries and enterprises in Singapore, JTC has pioneered and developed innovative infrastructure solutions to meet the unique needs of the biomedical industry.
One of these is Biopolis @ one-north, a world-class, purpose-built biomedical research and development hub. With 13 buildings across 5 phases and a total floor area of more than 340,000 square metres, it is a thriving ecosystem home to more than 50 public and private biomedical research organisations such as Abbott, Procter & Gamble (P&G) as well as the Agency for Science, Technology and Research (A*STAR), Singapore’s lead agency for scientific research and development.
It offers state-of-the-art facilities and amenities which cater to the needs of biomedical companies. To support the biomedical research community, Biopolis provides centralised infrastructure and services, saving time and cost for its tenants. The services include glassware washing, culture preparation and high-end scientific services such as mass spectrometry, DNA sequencing and X-ray crystallography. In addition, shared business facilities such as meetings rooms and auditoriums are also available.
To provide an intellectually stimulating environment for the working community, JTC has curated events like one-north Festival to provide a platform for the industry to come together and discuss about relevant topics. Beyond work, to bring the community closer, social events such as bi-weekly Fantastic Fridays and the annual one-north run were also introduced.
In conjunction with the BioPharma Asia Convention 2017, the World Orphan Drug Congress will be hosted at Biopolis. The World Orphan Drug Congress is the only rare disease meeting in Asia and it allows visitors to gain insights into expediting orphan drug development in Asia. We look forward to welcoming you at Biopolis on 21 March 2017. Follow us on https://www.facebook.com/jtccorp/.